Conclusions Compared with high-dose statin therapy , ezetimibe with low-dose statin for more than 3 months may have a beneficial tendency of effects on glycemic control
Purpose Given the increased risk of incident diabetes and the side effects on glycemic control with statin treatment , statin and ezetimibe combination therapy has been widely used .
However , whether the same concern exists in ezetimibe remains uncertain .
This meta- analysis aim ed to investigate the influence of ezetimibe treatment on glycemic control .
Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus.
OBJECTIVE The effectiveness of the cholesterol absorption inhibitor ezetimibe on LDL subfractions and ultimately on the atherosclerotic risk profile remains controversial . We thus determined the concentration of atherogenic small , dense LDL ( sdLDL ) in patients with type 2 diabetes and an elevated cardiovascular risk profile . RESEARCH DESIGN AND METHODS Multicenter , r and omized , open-label 6-week study investigating the effect of ezetimibe 10 mg ( E ) , simvastatin 20 mg ( S ) and the combination of ezetimibe-/simvastatin 10/20 mg ( C ) on the concentration of sdLDL separated from fresh plasma by gradient ultracentrifugation in patients with type 2 diabetes ( NCT01384058 ) . RESULTS Fifty-six patients were screened for sdLDL , 41 were r and omized , and 40 patients ( 12 E , 14 S and 14 C ) completed the study .  Total and LDL cholesterol fell by 14 % ( p=0.004 ) and 15 % ( p=0.006 ) with E , 22 % ( p<0.001 ) and 32 % ( p<0.001 ) with S , and 32 % ( p<0.001 ) and 44 % ( p<0.001 ) with C , respectively . E reduced the concentration of sdLDL by 20 % ( p=0.043 ) whereas S and C reduced sdLDL by 24 % ( p=0.020 ) and 33 % ( p=0.003 ) , respectively , and non-sdLDL by 28 % ( p=0.004 ) and 42 % ( p<0.001 ) , respectively . However , the further drop in sdLDL by adding E to S was not significant . CONCLUSION Ezetimibe alone and in combination with simvastatin reduced the concentration of atherogenic sdLDL in patients with type 2 diabetes
Conclusions Compared with high-dose statin therapy , ezetimibe with low-dose statin for more than 3 months may have a beneficial tendency of effects on glycemic control
Purpose Given the increased risk of incident diabetes and the side effects on glycemic control with statin treatment , statin and ezetimibe combination therapy has been widely used .
However , whether the same concern exists in ezetimibe remains uncertain .
This meta- analysis aim ed to investigate the influence of ezetimibe treatment on glycemic control .